NCT05176002 2025-11-19
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
Fujian Medical University Union Hospital
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05924997 2024-02-21
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT06010212 2023-08-24
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT05742750 2023-02-24
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT04231552 2020-11-30
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT04572542 2020-10-01
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
The First Affiliated Hospital of Xiamen University
Phase 1/2 Unknown
NCT04202978 2020-04-16
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
Zhongshan Hospital Xiamen University
Phase 1/2 Unknown
NCT04298320 2020-03-16
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
Harbin Medical University
Phase 1/2 Unknown
NCT04286711 2020-02-27
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
China Medical University, China
Phase 1/2 Unknown
NCT04182724 2019-12-03
Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04035876 2019-07-29
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
Phase 1/2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown